NVIDIA launches Jetson Thor robotics computers for physical AI systems
Horn Howard, the Chief Financial Officer of Ultragenyx Pharmaceutical (TADAWUL:2070) Inc. (NASDAQ:RARE), recently sold 1,785 shares of the company’s common stock. The transaction, which took place on March 6, 2025, was valued at approximately $72,114. The sale comes as the company’s stock trades near its 52-week low of $37.02, with InvestingPro analysis indicating the stock is currently undervalued. The shares were sold at a weighted average price of $40.4 per share, with the sale occurring in multiple transactions at prices ranging from $39.73 to $41.37. Following this sale, Howard retains ownership of 106,169 shares in the company. The $3.49 billion market cap company maintains strong liquidity with a current ratio of 2.37, though it operates with moderate debt levels. Get deeper insights into RARE’s financial health and access exclusive analysis with InvestingPro’s comprehensive research report.
The sale was executed to cover required tax withholdings due to the vesting of restricted stock units (RSUs). These RSUs are subject to certain vesting conditions, as previously reported. While the company faces profitability challenges with a net loss in the last twelve months, its liquid assets exceed short-term obligations, providing financial stability during this growth phase.
In other recent news, Ultragenyx Pharmaceutical Inc. reported fourth-quarter 2024 earnings that exceeded expectations, driven by strong sales from its Crysvita, Dojolvi, and Evkeeza product lines. Canaccord Genuity responded to these results by raising its price target for Ultragenyx to $136 and maintaining a Buy rating. Similarly, Goldman Sachs reiterated its Buy rating with a $78 target, highlighting the company’s total revenue of $164.9 million, which surpassed both Goldman Sachs and Visible Alpha Consensus estimates.
H.C. Wainwright also maintained a Buy rating with a $95 target, noting the FDA’s acceptance of Ultragenyx’s Biologics License Application for the gene therapy UX111, targeting Sanfilippo syndrome type A. The FDA set a PDUFA action date for August 18, 2025, a significant milestone for the company. Cantor Fitzgerald reiterated its Overweight rating with a $118 target, emphasizing the progress in Ultragenyx’s gene therapy programs, including the DTX301 for OTC deficiency.
The firm’s analysts highlighted the upcoming clinical readouts for setrusumab in osteogenesis imperfecta, expected in mid-2025, as potential catalysts. Ultragenyx has expressed readiness to launch UX111 upon potential FDA approval, aligning with its strategy to achieve full-year GAAP profitability by 2027. The company’s promising pipeline and forthcoming product launches continue to attract attention from analysts and investors alike.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.